Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

The main problem is that Nader talks too

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
lorbas95 Member Profile
 
Followed By 1
Posts 244
Boards Moderated 0
Alias Born 01/10/19
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/20/2019 12:14:59 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 11/20/2019 12:12:39 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/20/2019 9:26:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/20/2019 9:06:31 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2019 11:35:19 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 8:31:48 AM
Amended Small Company Offering and Sale of Securities Without Registration (d/a) Edgar (US Regulatory) - 11/12/2019 7:07:38 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/7/2019 9:13:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2019 8:36:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/31/2019 5:07:01 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/22/2019 8:16:54 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/8/2019 7:10:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/8/2019 7:06:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/8/2019 7:05:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/8/2019 7:04:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/8/2019 7:03:53 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 10/8/2019 5:26:49 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/3/2019 9:04:31 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/3/2019 8:34:28 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/1/2019 6:01:12 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 9/30/2019 4:13:58 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/27/2019 6:02:58 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/19/2019 9:19:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/19/2019 8:39:45 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 5:14:14 PM
lorbas95   Monday, 10/21/19 10:38:05 AM
Re: bcgk post# 47501
Post # of 49445 
The main problem is that Nader talks too much and gives too optimistic timelines. And I don't understand some strategic decisions of the past like delaying GvHD, not raising a big chunk at once to avoid a slow bleeding etc., that offer for "loyal shareholders", prognostic test, not outlicensing certain territories...

A lot of the delay is on the FDA who insists on more and more data for a immensely efficacious and safe product for patients with very limited treatment options...

Considering all the facts, even in a worst case scenario with 1b or 2b shares, it should be worth much more than .30 or $1, although SP would suffer a lot mid-term. So, yes, from this perspective, IMO CYDY is derisked, but of course not totally derisked, if the FDA should demand further data (which at this point seems rather unlikely though). All the clinical data seem excellent too; manufacturing portion is in the hand of Samsung. Risk of a CRL after BLA submission is very low IMO.

I don't think anyone here would say that risk is 0%, but after looking at all the available information, it seems like a great investment long-term. And that is what ohm and others try to say, as far as I understand it...







Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist